Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials

Overview

Enlaza Therapeutics is pioneering the field of covalent biologics, developing a novel classes of protein therapeutics based on its proprietary War-Lock™ platform.

Connections

List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors1
634 portfolio companies

News

Report
News Chemical & Engineering News 2 years ago
Enlaza Therapeutics raises $100 million series A to improve drug targeting
Chemical & Engineering News (C&EN): Keeping you up to date with the chemistry news that matters most. Published by the American Chemical Society.
Read more
Report
News Pulse 2.0 2 years ago
Enlaza Therapeutics: Covalent Biologic Platform Company Secures $100 Million
Covalent biologic platform company Enlaza Therapeutics announced a $100 million Series A funding round. This round of funding will be used to develop Enlaza's proprietary covalent protein technologies further and support the advancement of wholly owned pi
Read more
Report
Press release businesswire 2 years ago
Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital
Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital
Read more
Report

People

Sergio Duron
Executive Officer, Director
Sanford Madigan
Executive Officer
Tighe Reardon
Executive Officer
Jay Lichter
Director
Shelley Chu
Director
James Topper
Director
Marcos Milla
Director
Stephen Squinto
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
La Jolla United States
HQ
200-500 est. staff

Financials

Total raised
$134.3M
Latest round
Venture - Series Unknown
Funding rounds
3
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $15M Details
Venture - Series Unknown 2024 $84M Details
Venture - Series Unknown 2021 $35.3M Details